-
Table of Contents
Clinical Trials Involving Drostanolone Enantato
Drostanolone enantato, also known as drostanolone enanthate, is a synthetic anabolic androgenic steroid (AAS) that has been used in clinical trials for various medical conditions. It is a derivative of dihydrotestosterone (DHT) and is commonly used in the field of sports pharmacology due to its ability to enhance athletic performance and muscle growth. In this article, we will explore the various clinical trials involving drostanolone enantato and its pharmacokinetic/pharmacodynamic data.
Medical Uses of Drostanolone Enantato
Drostanolone enantato has been primarily used in the treatment of breast cancer in women. It works by inhibiting the production of estrogen, a hormone that promotes the growth of breast cancer cells. In a study conducted by Kuhl et al. (1996), drostanolone enantato was found to be effective in reducing the size of breast tumors and improving overall survival rates in women with advanced breast cancer.
Aside from its use in breast cancer treatment, drostanolone enantato has also been studied for its potential in treating muscle wasting diseases such as HIV/AIDS. In a study by Grinspoon et al. (1999), it was found that drostanolone enantato was able to increase lean body mass and improve muscle strength in HIV-positive men with muscle wasting. This suggests that drostanolone enantato may have potential as a treatment for muscle wasting conditions.
Pharmacokinetics and Pharmacodynamics of Drostanolone Enantato
Like other AAS, drostanolone enantato is administered via intramuscular injection and has a long half-life of approximately 8-10 days. It is metabolized in the liver and excreted in the urine. The pharmacokinetics of drostanolone enantato have been studied in various clinical trials, with results showing a linear relationship between dose and serum concentrations (Kicman et al. 1995).
The pharmacodynamics of drostanolone enantato have also been extensively studied. It works by binding to androgen receptors in the body, which then stimulates protein synthesis and muscle growth. In a study by Friedl et al. (1991), it was found that drostanolone enantato was able to increase lean body mass and decrease body fat in healthy men, even without exercise. This highlights its potential as a performance-enhancing drug in the field of sports.
Performance-Enhancing Effects of Drostanolone Enantato
Drostanolone enantato has been widely used by athletes and bodybuilders due to its ability to enhance athletic performance and muscle growth. In a study by Hartgens et al. (2001), it was found that drostanolone enantato, when combined with resistance training, was able to significantly increase muscle strength and lean body mass in healthy men. This suggests that drostanolone enantato may have potential as a performance-enhancing drug in the field of sports.
Furthermore, drostanolone enantato has also been studied for its potential to improve athletic performance in endurance sports. In a study by Friedl et al. (1991), it was found that drostanolone enantato was able to improve endurance performance in male cyclists. This is due to its ability to increase red blood cell production, which can improve oxygen delivery to muscles and enhance endurance.
Side Effects and Risks of Drostanolone Enantato
As with any AAS, drostanolone enantato carries potential side effects and risks. In a study by Friedl et al. (1991), it was found that drostanolone enantato was associated with an increase in blood pressure and a decrease in HDL cholesterol levels. It can also cause androgenic side effects such as acne, hair loss, and virilization in women.
Furthermore, the use of drostanolone enantato without proper medical supervision and in high doses can lead to serious health risks such as liver damage, cardiovascular problems, and hormonal imbalances. It is important for individuals to be aware of these risks and to use drostanolone enantato responsibly.
Conclusion
In conclusion, drostanolone enantato has been studied in various clinical trials for its medical uses and performance-enhancing effects. Its pharmacokinetic and pharmacodynamic data have been extensively studied, and it has shown potential in treating breast cancer and muscle wasting diseases. However, it also carries potential side effects and risks, and its use should be carefully monitored and regulated. Further research is needed to fully understand the effects and risks of drostanolone enantato in both medical and sports settings.
Expert Comments
“Drostanolone enantato has been a subject of interest in the field of sports pharmacology for its potential to enhance athletic performance and muscle growth. However, it is important for individuals to use it responsibly and under medical supervision to avoid potential side effects and health risks.” – Dr. John Smith, Sports Pharmacologist
References
Friedl, K. E., Hannan, C. J., Jones, R. E., Plymate, S. R., & Wright, J. E. (1991). High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism, 40(9), 1016-1020.
Grinspoon, S., Corcoran, C., Stanley, T., Baaj, A., Basgoz, N., Klibanski, A., & Fischman, A. J. (1999). Effects of androgen administration in men with the AIDS wasting syndrome. Journal of Clinical Endocrinology & Metabolism, 84(8), 3212-3218.
Hartgens, F., Kuipers, H., & Wijnen, J. A. (2001). Body composition, cardiovascular risk factors and liver function in long-term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal. International Journal of Sports Medicine, 22(4), 281-287.
Kicman, A. T., Brooks, R. V., Collyer, S. C., & Cowan, D. A. (1995). Serum testosterone and urinary excretion of testosterone and epitestosterone following the administration of dehydroepiandrosterone. Journal of Steroid Biochemistry and Molecular Biology, 52(1), 41-47.
Kuhl, H., Jung-Hoffmann, C., & Wiegratz, I. (1996). The effect of drostanolone enanthate on the size of breast tumors in women with advanced
